Blood & Plasma Components Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027 Segmented By Products (Packed Red Blood Cells, Platelets Products, Frozen Plasma, Plasma Derived Products), By Application (Hematology, Solid Tumor Management, Others), By End User (Hospitals & Clinics, Diagnostic Laboratories, Others), By company and By Region
The global blood & plasma components market is anticipated to observe impressive growth during the forecast period, 2023-2027. The major factors include the growing volume of surgeries, the surge in the prevalence of trauma and road accidents, and the increase in the number of people from chronic conditions, including cancer are curbing the growth of the market. Blood is a life-sustaining fluid that flows throughout the body, giving nourishment, electrolytes, hormones, antibodies, and vitamins to body tissues. Plasma is a part of the blood which is aqueous in nature; it contains salt and proteins in which platelets, white blood cells, and red blood cells are suspended. The other factors supporting the market’s growth are, rising awareness associated with the significance of blood donations, high patient pool, government initiatives, increasing investments for research and development activities, several blood donation campaigns undertaken by various blood organizations, rise in the elderly population base, rise in R&D activities, and technological advancements. Also, the strategic initiatives such as partnerships and product launches undertaken by the market players are augmenting the growth of the market.
Increasing Occurrence of Trauma and Road Accidents
The growing incidence of trauma and road accidents is a significant factor propelling the growth of the market. At times, people suffer from traumas such as hemorrhage; the amount of blood present gets reduced and cannot be replaced fast enough by the body. According to a review, in 2018, approximately 60,000 Americans died from hemorrhaging or blood loss every year. Also, owing to the rise in the number of road accidents, excessive blood loss from the body is raising the demand for blood or plasma transfusion to prevent bleeding. Thus, in turn, these situations are augmenting the growth of the blood and plasma component market globally. According to WHO research, in 2020, nearly 1.5 million people died every year due to road traffic injuries around the globe.
Rising Frequency of Blood Diseases and Surgeries
The growing incidences of bleeding disorders and the rising number of surgeries across the globe are bolstering the growth of the market. Hemophilia A and B and von Willebrand disease are the most common bleeding disorders. For instance, in 2019, 195,263 people globally were diagnosed with hemophilia, and 80,302 were diagnosed with von Willebrand disease. In addition to these, increasing cases of surgeries are impelling the growth of the market as a lot of blood is lost during the operations, which increases the chances of needing transfusions. Also, the demand for blood transfusion rises in patients who are anemic. For instance, approximately 310 million major surgeries are performed every year globally, of which 50 million are in the USA, and 20 million are in Europe.
Increasing Adoption of Inorganic Growth Strategies
Various inorganic growth strategies such as mergers, collaborations, acquisitions, and partnerships are supporting the growth of the market. For instance, the Blood Center of Wisconsin collaborated with SysLogic Inc. to research how RFID technology can be utilized to heighten the safety of the patient while collecting and transfusing blood products. Similarly, in 2018, Invitrx Inc. launched a cord blood plasma product that contains plasticity-promoting proteins that may have anti-aging effects that increase neurogenesis and cognitive function.
Market Segmentation
The global blood & plasma components market is segmented into products, applications, end user, and company. Based on products, the market is divided into packed red blood cells, platelets products, frozen plasma, and plasma-derived products. Based on plasma-derived products, the market is further divided into immunoglobulins, albumins, coagulation factor concentrates, and others. Based on application, the market is divided into hematology, solid tumor management, and others. Based on hematology, the market is further divided into hemoglobinopathy, hematologic malignancies treatment, coagulopathy, and others. Based on end-user, the market is divided into hospitals & clinics, diagnostic laboratories, and others. In terms of country, the United States is expected to be a lucrative market in the forecast period due to the rising number of chronic diseases and surgeries in the country.
Market Players
CSL Limited, Grifols S.A., ADMA Biologics, Inc., Takeda Pharmaceutical Company Limited, Octapharma AG, Kedrion S.p.A, Emergent BioSolutions Inc., Bio Products Laboratory Ltd., LFB S.A., and Versiti, Inc. are some of the leading companies operating in the market.
Report Scope:
In this report, global blood & plasma components market has been segmented into following categories, in addition to the industry trends which have also been detailed below:
Company Profiles: Detailed analysis of the major companies present in Global Blood & Plasma Components Market
Available Customizations:
With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:
Company Information
Increasing Occurrence of Trauma and Road Accidents
The growing incidence of trauma and road accidents is a significant factor propelling the growth of the market. At times, people suffer from traumas such as hemorrhage; the amount of blood present gets reduced and cannot be replaced fast enough by the body. According to a review, in 2018, approximately 60,000 Americans died from hemorrhaging or blood loss every year. Also, owing to the rise in the number of road accidents, excessive blood loss from the body is raising the demand for blood or plasma transfusion to prevent bleeding. Thus, in turn, these situations are augmenting the growth of the blood and plasma component market globally. According to WHO research, in 2020, nearly 1.5 million people died every year due to road traffic injuries around the globe.
Rising Frequency of Blood Diseases and Surgeries
The growing incidences of bleeding disorders and the rising number of surgeries across the globe are bolstering the growth of the market. Hemophilia A and B and von Willebrand disease are the most common bleeding disorders. For instance, in 2019, 195,263 people globally were diagnosed with hemophilia, and 80,302 were diagnosed with von Willebrand disease. In addition to these, increasing cases of surgeries are impelling the growth of the market as a lot of blood is lost during the operations, which increases the chances of needing transfusions. Also, the demand for blood transfusion rises in patients who are anemic. For instance, approximately 310 million major surgeries are performed every year globally, of which 50 million are in the USA, and 20 million are in Europe.
Increasing Adoption of Inorganic Growth Strategies
Various inorganic growth strategies such as mergers, collaborations, acquisitions, and partnerships are supporting the growth of the market. For instance, the Blood Center of Wisconsin collaborated with SysLogic Inc. to research how RFID technology can be utilized to heighten the safety of the patient while collecting and transfusing blood products. Similarly, in 2018, Invitrx Inc. launched a cord blood plasma product that contains plasticity-promoting proteins that may have anti-aging effects that increase neurogenesis and cognitive function.
Market Segmentation
The global blood & plasma components market is segmented into products, applications, end user, and company. Based on products, the market is divided into packed red blood cells, platelets products, frozen plasma, and plasma-derived products. Based on plasma-derived products, the market is further divided into immunoglobulins, albumins, coagulation factor concentrates, and others. Based on application, the market is divided into hematology, solid tumor management, and others. Based on hematology, the market is further divided into hemoglobinopathy, hematologic malignancies treatment, coagulopathy, and others. Based on end-user, the market is divided into hospitals & clinics, diagnostic laboratories, and others. In terms of country, the United States is expected to be a lucrative market in the forecast period due to the rising number of chronic diseases and surgeries in the country.
Market Players
CSL Limited, Grifols S.A., ADMA Biologics, Inc., Takeda Pharmaceutical Company Limited, Octapharma AG, Kedrion S.p.A, Emergent BioSolutions Inc., Bio Products Laboratory Ltd., LFB S.A., and Versiti, Inc. are some of the leading companies operating in the market.
Report Scope:
In this report, global blood & plasma components market has been segmented into following categories, in addition to the industry trends which have also been detailed below:
- Blood & Plasma Components Market, By Products:
- Packed Red Blood Cells
- Platelets Products
- Frozen Plasma
- Plasma Derived Products
- Immunoglobulins
- Albumins
- Coagulation Factor Concentrates
- Others
- Blood & Plasma Components Market, By Application:
- Hematology
- Hemoglobinopathy
- Hematologic Malignancies Treatment
- Coagulopathy
- Others
- Solid Tumor Management
- Others
- Blood & Plasma Components Market, By End User:
- Hospitals & Clinics
- Diagnostic Laboratories
- Others
- Blood & Plasma Components Market, By Region:
- North America
- United States
- Canada
- Mexico
- Asia-Pacific
- China
- India
- Japan
- Australia
- South Korea
- Europe & CIS
- Germany
- France
- United Kingdom
- Spain
- Italy
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
Company Profiles: Detailed analysis of the major companies present in Global Blood & Plasma Components Market
Available Customizations:
With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
1. PRODUCT OVERVIEW
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. IMPACT OF COVID-19 ON GLOBAL BLOOD & PLASMA COMPONENTS MARKET
5. VOICE OF CUSTOMER
6. GLOBAL BLOOD & PLASMA COMPONENTS MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Products (Packed Red Blood Cells, Platelets Products, Frozen Plasma, Plasma Derived Products)
6.2.1.1. By Plasma Derived Products (Immunoglobulins, Albumins, Coagulation Factor Concentrates, Others)
6.2.2. By Application (Hematology, Solid Tumor Management, Others)
6.2.2.1. By Hematology (Hemoglobinopathy, Hematologic Malignancies Treatment, Coagulopathy, Others)
6.2.3. By End User (Hospitals & Clinics, Diagnostic Laboratories, Others)
6.2.4. By Company (2021)
6.2.5. By Region
6.3. Market Map
7. NORTH AMERICA BLOOD & PLASMA COMPONENTS MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Products (Packed Red Blood Cells, Platelets Products, Frozen Plasma, Plasma Derived Products)
7.2.1.1. By Plasma Derived Products (Immunoglobulins, Albumins, Coagulation Factor Concentrates, Others)
7.2.2. By Application (Hematology, Solid Tumor Management, Others)
7.2.2.1. By Hematology (Hemoglobinopathy, Hematologic Malignancies Treatment, Coagulopathy, Others)
7.2.3. By End User (Hospitals & Clinics, Diagnostic Laboratories, Others)
7.2.4. By Country
7.3. North America: Country Analysis
7.3.1. United States Blood & Plasma Components Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Products
7.3.1.2.2. By Application
7.3.1.2.3. By End User
7.3.2. Canada Blood & Plasma Components Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Products
7.3.2.2.2. By Application
7.3.2.2.3. By End User
7.3.3. Mexico Blood & Plasma Components Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Products
7.3.3.2.2. By Application
7.3.3.2.3. By End User
8. EUROPE BLOOD & PLASMA COMPONENTS MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Products (Packed Red Blood Cells, Platelets Products, Frozen Plasma, Plasma Derived Products)
8.2.1.1. By Plasma Derived Products (Immunoglobulins, Albumins, Coagulation Factor Concentrates, Others)
8.2.2. By Application (Hematology, Solid Tumor Management, Others)
8.2.2.1. By Hematology (Hemoglobinopathy, Hematologic Malignancies Treatment, Coagulopathy, Others)
8.2.3. By End User (Hospitals & Clinics, Diagnostic Laboratories, Others)
8.2.4. By Country
8.3. Europe: Country Analysis
8.3.1. France Blood & Plasma Components Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Products
8.3.1.2.2. By Application
8.3.1.2.3. By End User
8.3.2. Germany Blood & Plasma Components Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Products
8.3.2.2.2. By Application
8.3.2.2.3. By End User
8.3.3. United Kingdom Blood & Plasma Components Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Products
8.3.3.2.2. By Application
8.3.3.2.3. By End User
8.3.4. Italy Blood & Plasma Components Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Products
8.3.4.2.2. By Application
8.3.4.2.3. By End User
8.3.5. Spain Blood & Plasma Components Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Products
8.3.5.2.2. By Application
8.3.5.2.3. By End User
9. ASIA-PACIFIC BLOOD & PLASMA COMPONENTS MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Products (Packed Red Blood Cells, Platelets Products, Frozen Plasma, Plasma Derived Products)
9.2.1.1. By Plasma Derived Products (Immunoglobulins, Albumins, Coagulation Factor Concentrates, Others)
9.2.2. By Application (Hematology, Solid Tumor Management, Others)
9.2.2.1. By Hematology (Hemoglobinopathy, Hematologic Malignancies Treatment, Coagulopathy, Others)
9.2.3. By End User (Hospitals & Clinics, Diagnostic Laboratories, Others)
9.2.4. By Country
9.3. Asia-Pacific: Country Analysis
9.3.1. China Blood & Plasma Components Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Products
9.3.1.2.2. By Application
9.3.1.2.3. By End User
9.3.2. India Blood & Plasma Components Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Products
9.3.2.2.2. By Application
9.3.2.2.3. By End User
9.3.3. Japan Blood & Plasma Components Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Products
9.3.3.2.2. By Application
9.3.3.2.3. By End User
9.3.4. South Korea Blood & Plasma Components Market Outlook
9.3.4.1. Market Size & Forecast
9.3.4.1.1. By Value
9.3.4.2. Market Share & Forecast
9.3.4.2.1. By Products
9.3.4.2.2. By Application
9.3.4.2.3. By End User
9.3.5. Australia Blood & Plasma Components Market Outlook
9.3.5.1. Market Size & Forecast
9.3.5.1.1. By Value
9.3.5.2. Market Share & Forecast
9.3.5.2.1. By Products
9.3.5.2.2. By Application
9.3.5.2.3. By End User
10. SOUTH AMERICA BLOOD & PLASMA COMPONENTS MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Products (Packed Red Blood Cells, Platelets Products, Frozen Plasma, Plasma Derived Products)
10.2.1.1. By Plasma Derived Products (Immunoglobulins, Albumins, Coagulation Factor Concentrates, Others)
10.2.2. By Application (Hematology, Solid Tumor Management, Others)
10.2.2.1. By Hematology (Hemoglobinopathy, Hematologic Malignancies Treatment, Coagulopathy, Others)
10.2.3. By End User (Hospitals & Clinics, Diagnostic Laboratories, Others)
10.2.4. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Blood & Plasma Components Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Products
10.3.1.2.2. By Application
10.3.1.2.3. By End User
10.3.2. Argentina Blood & Plasma Components Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Products
10.3.2.2.2. By Application
10.3.2.2.3. By End User
10.3.3. Colombia Blood & Plasma Components Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Products
10.3.3.2.2. By Application
10.3.3.2.3. By End User
11. MIDDLE EAST AND AFRICA BLOOD & PLASMA COMPONENTS MARKET OUTLOOK
11.1. Market Size & Forecast
11.1.1. By Value
11.2. Market Share & Forecast
11.2.1. By Products (Packed Red Blood Cells, Platelets Products, Frozen Plasma, Plasma Derived Products)
11.2.1.1. By Plasma Derived Products (Immunoglobulins, Albumins, Coagulation Factor Concentrates, Others)
11.2.2. By Application (Hematology, Solid Tumor Management, Others)
11.2.2.1. By Hematology (Hemoglobinopathy, Hematologic Malignancies Treatment, Coagulopathy, Others)
11.2.3. By End User (Hospitals & Clinics, Diagnostic Laboratories, Others)
11.2.4. By Country
11.3. MEA: Country Analysis
11.3.1. South Africa Blood & Plasma Components Market Outlook
11.3.1.1. Market Size & Forecast
11.3.1.1.1. By Value
11.3.1.2. Market Share & Forecast
11.3.1.2.1. By Products
11.3.1.2.2. By Application
11.3.1.2.3. By End User
11.3.2. Saudi Arabia Blood & Plasma Components Market Outlook
11.3.2.1. Market Size & Forecast
11.3.2.1.1. By Value
11.3.2.2. Market Share & Forecast
11.3.2.2.1. By Products
11.3.2.2.2. By Application
11.3.2.2.3. By End User
11.3.3. UAE Blood & Plasma Components Market Outlook
11.3.3.1. Market Size & Forecast
11.3.3.1.1. By Value
11.3.3.2. Market Share & Forecast
11.3.3.2.1. By Products
11.3.3.2.2. By Application
11.3.3.2.3. By End User
12. MARKET DYNAMICS
12.1. Drivers
12.2. Challenges
13. MARKET TRENDS & DEVELOPMENTS
14. COMPETITIVE LANDSCAPE
14.1. CSL Limited
14.2. Grifols S.A.
14.3. ADMA Biologics, Inc.
14.4. Takeda Pharmaceutical Company Limited
14.5. Octapharma AG
14.6. Kedrion S.p.A
14.7. Emergent BioSolutions Inc.
14.8. Bio Products Laboratory Ltd.
14.9. LFB S.A.
14.10. Versiti, Inc.
15. STRATEGIC RECOMMENDATIONS
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. IMPACT OF COVID-19 ON GLOBAL BLOOD & PLASMA COMPONENTS MARKET
5. VOICE OF CUSTOMER
6. GLOBAL BLOOD & PLASMA COMPONENTS MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Products (Packed Red Blood Cells, Platelets Products, Frozen Plasma, Plasma Derived Products)
6.2.1.1. By Plasma Derived Products (Immunoglobulins, Albumins, Coagulation Factor Concentrates, Others)
6.2.2. By Application (Hematology, Solid Tumor Management, Others)
6.2.2.1. By Hematology (Hemoglobinopathy, Hematologic Malignancies Treatment, Coagulopathy, Others)
6.2.3. By End User (Hospitals & Clinics, Diagnostic Laboratories, Others)
6.2.4. By Company (2021)
6.2.5. By Region
6.3. Market Map
7. NORTH AMERICA BLOOD & PLASMA COMPONENTS MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Products (Packed Red Blood Cells, Platelets Products, Frozen Plasma, Plasma Derived Products)
7.2.1.1. By Plasma Derived Products (Immunoglobulins, Albumins, Coagulation Factor Concentrates, Others)
7.2.2. By Application (Hematology, Solid Tumor Management, Others)
7.2.2.1. By Hematology (Hemoglobinopathy, Hematologic Malignancies Treatment, Coagulopathy, Others)
7.2.3. By End User (Hospitals & Clinics, Diagnostic Laboratories, Others)
7.2.4. By Country
7.3. North America: Country Analysis
7.3.1. United States Blood & Plasma Components Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Products
7.3.1.2.2. By Application
7.3.1.2.3. By End User
7.3.2. Canada Blood & Plasma Components Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Products
7.3.2.2.2. By Application
7.3.2.2.3. By End User
7.3.3. Mexico Blood & Plasma Components Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Products
7.3.3.2.2. By Application
7.3.3.2.3. By End User
8. EUROPE BLOOD & PLASMA COMPONENTS MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Products (Packed Red Blood Cells, Platelets Products, Frozen Plasma, Plasma Derived Products)
8.2.1.1. By Plasma Derived Products (Immunoglobulins, Albumins, Coagulation Factor Concentrates, Others)
8.2.2. By Application (Hematology, Solid Tumor Management, Others)
8.2.2.1. By Hematology (Hemoglobinopathy, Hematologic Malignancies Treatment, Coagulopathy, Others)
8.2.3. By End User (Hospitals & Clinics, Diagnostic Laboratories, Others)
8.2.4. By Country
8.3. Europe: Country Analysis
8.3.1. France Blood & Plasma Components Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Products
8.3.1.2.2. By Application
8.3.1.2.3. By End User
8.3.2. Germany Blood & Plasma Components Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Products
8.3.2.2.2. By Application
8.3.2.2.3. By End User
8.3.3. United Kingdom Blood & Plasma Components Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Products
8.3.3.2.2. By Application
8.3.3.2.3. By End User
8.3.4. Italy Blood & Plasma Components Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Products
8.3.4.2.2. By Application
8.3.4.2.3. By End User
8.3.5. Spain Blood & Plasma Components Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Products
8.3.5.2.2. By Application
8.3.5.2.3. By End User
9. ASIA-PACIFIC BLOOD & PLASMA COMPONENTS MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Products (Packed Red Blood Cells, Platelets Products, Frozen Plasma, Plasma Derived Products)
9.2.1.1. By Plasma Derived Products (Immunoglobulins, Albumins, Coagulation Factor Concentrates, Others)
9.2.2. By Application (Hematology, Solid Tumor Management, Others)
9.2.2.1. By Hematology (Hemoglobinopathy, Hematologic Malignancies Treatment, Coagulopathy, Others)
9.2.3. By End User (Hospitals & Clinics, Diagnostic Laboratories, Others)
9.2.4. By Country
9.3. Asia-Pacific: Country Analysis
9.3.1. China Blood & Plasma Components Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Products
9.3.1.2.2. By Application
9.3.1.2.3. By End User
9.3.2. India Blood & Plasma Components Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Products
9.3.2.2.2. By Application
9.3.2.2.3. By End User
9.3.3. Japan Blood & Plasma Components Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Products
9.3.3.2.2. By Application
9.3.3.2.3. By End User
9.3.4. South Korea Blood & Plasma Components Market Outlook
9.3.4.1. Market Size & Forecast
9.3.4.1.1. By Value
9.3.4.2. Market Share & Forecast
9.3.4.2.1. By Products
9.3.4.2.2. By Application
9.3.4.2.3. By End User
9.3.5. Australia Blood & Plasma Components Market Outlook
9.3.5.1. Market Size & Forecast
9.3.5.1.1. By Value
9.3.5.2. Market Share & Forecast
9.3.5.2.1. By Products
9.3.5.2.2. By Application
9.3.5.2.3. By End User
10. SOUTH AMERICA BLOOD & PLASMA COMPONENTS MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Products (Packed Red Blood Cells, Platelets Products, Frozen Plasma, Plasma Derived Products)
10.2.1.1. By Plasma Derived Products (Immunoglobulins, Albumins, Coagulation Factor Concentrates, Others)
10.2.2. By Application (Hematology, Solid Tumor Management, Others)
10.2.2.1. By Hematology (Hemoglobinopathy, Hematologic Malignancies Treatment, Coagulopathy, Others)
10.2.3. By End User (Hospitals & Clinics, Diagnostic Laboratories, Others)
10.2.4. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Blood & Plasma Components Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Products
10.3.1.2.2. By Application
10.3.1.2.3. By End User
10.3.2. Argentina Blood & Plasma Components Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Products
10.3.2.2.2. By Application
10.3.2.2.3. By End User
10.3.3. Colombia Blood & Plasma Components Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Products
10.3.3.2.2. By Application
10.3.3.2.3. By End User
11. MIDDLE EAST AND AFRICA BLOOD & PLASMA COMPONENTS MARKET OUTLOOK
11.1. Market Size & Forecast
11.1.1. By Value
11.2. Market Share & Forecast
11.2.1. By Products (Packed Red Blood Cells, Platelets Products, Frozen Plasma, Plasma Derived Products)
11.2.1.1. By Plasma Derived Products (Immunoglobulins, Albumins, Coagulation Factor Concentrates, Others)
11.2.2. By Application (Hematology, Solid Tumor Management, Others)
11.2.2.1. By Hematology (Hemoglobinopathy, Hematologic Malignancies Treatment, Coagulopathy, Others)
11.2.3. By End User (Hospitals & Clinics, Diagnostic Laboratories, Others)
11.2.4. By Country
11.3. MEA: Country Analysis
11.3.1. South Africa Blood & Plasma Components Market Outlook
11.3.1.1. Market Size & Forecast
11.3.1.1.1. By Value
11.3.1.2. Market Share & Forecast
11.3.1.2.1. By Products
11.3.1.2.2. By Application
11.3.1.2.3. By End User
11.3.2. Saudi Arabia Blood & Plasma Components Market Outlook
11.3.2.1. Market Size & Forecast
11.3.2.1.1. By Value
11.3.2.2. Market Share & Forecast
11.3.2.2.1. By Products
11.3.2.2.2. By Application
11.3.2.2.3. By End User
11.3.3. UAE Blood & Plasma Components Market Outlook
11.3.3.1. Market Size & Forecast
11.3.3.1.1. By Value
11.3.3.2. Market Share & Forecast
11.3.3.2.1. By Products
11.3.3.2.2. By Application
11.3.3.2.3. By End User
12. MARKET DYNAMICS
12.1. Drivers
12.2. Challenges
13. MARKET TRENDS & DEVELOPMENTS
14. COMPETITIVE LANDSCAPE
14.1. CSL Limited
14.2. Grifols S.A.
14.3. ADMA Biologics, Inc.
14.4. Takeda Pharmaceutical Company Limited
14.5. Octapharma AG
14.6. Kedrion S.p.A
14.7. Emergent BioSolutions Inc.
14.8. Bio Products Laboratory Ltd.
14.9. LFB S.A.
14.10. Versiti, Inc.
15. STRATEGIC RECOMMENDATIONS
